In their fifth collaboration together, AstraZeneca and Daiichi Sankyo have partnered up to develop and commercialise the latter’s lead antibody drug conjugate therapy, trastuzumab deruxtecan (DS-8201), for the treatment of breast and gastric cancers which are connected to the HER2 gene. Data from the ongoing first-time-in-human trial showed strong activity in a number of tumour types and a regulatory submission is expected to be filed in the second half of 2019.